Matthew Pillar
Chief Editor at Bioprocess Online
Host at Business Of Biotech
Host, Business of Biotech Podcast. Editor, Bioprocess Online. I like it better on LinkedIn -- follow me there! https://t.co/7rwRY0AdUD
Articles
-
Dec 3, 2024 |
bioprocessonline.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online COUR Pharmaceuticals has been, as its newly-appointed President & CEO Dannielle Appelhans puts it, flying under the radar for a long time. COUR made a splash back in 2015, when it formed up around a biodegradable nanoparticle encapsulating gliadin proteins that proved to reverse the effects of gluten in animal models.
-
Oct 30, 2024 |
bioprocessonline.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online Way back in November 2021, Cidara Therapeutics entered into a collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of J&J, to advance the development of Cidara’s lead drug-Fc conjugate (DFC), a compound called CD388 that was pre-clinical at the time.
-
Oct 17, 2024 |
bioprocessonline.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online Lexeo Therapeutics VP of Analytical Development & Quality Timothy Fenn, Ph.D. took the stage at the ribbon cutting ceremony for MilliporeSigma’s new $3.2 million biosafety testing facility in Rockville, Maryland last week.
-
Oct 17, 2024 |
biosimilardevelopment.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online Lexeo Therapeutics VP of Analytical Development & Quality Timothy Fenn, Ph.D. took the stage at the ribbon cutting ceremony for MilliporeSigma’s new $3.2 million biosafety testing facility in Rockville, Maryland last week.
-
Oct 7, 2024 |
outsourcedpharma.com | Matthew Pillar |Irwin Hirsh |Q-Specialists AB |Louis Garguilo
Breaking Barriers: Combining Cell Line Development Innovation with Improved Process Development Workflows to Streamline Path to FIHThis webinar will focus on how KBI Biopharma's SUREtechnology Platform™, powered by Selexis®, enables rapid advancement of new complex biologics from early development to first-in-human (FIH). Register to learn how the integration of the SUREtechnology Platform™ accelerates the creation of high-performing, stable cell lines tailored for biologics production.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 606
- DMs Open
- No
RT @Bob_Hetu: Retailers increasingly not accepting #cash in the US market. The excuse is a lack of circulation of cash due to #COVID19 doe…
I really leaned in to @Allan_L_Shaw's #startup financing knowledge base for this candid conversation on the ins and outs of a special purpose acquisition company, or #SPAC, as a biopharma finance vehicle. He was definitely the man to ask. Via BioProcess O…https://t.co/zCe4290TDG
Want to know what process intensification is, the results it drives, the challenges it presents, and how to implement it in your upstream #bioprocessing environment? Join Sonnet BioTherapeutics, Inc. CTO Susan Dexter, single-use an…https://t.co/VlUpKKHnfx https://t.co/VCVehGRscA